Key Points - Kaplan Fox & Kilsheimer LLP announces securities fraud class action lawsuit against Hyliion Holdings Corp. - Investors who suffered losses urged to join the case. - Law Offices of Howard G. Smith reminds investors of upcoming filing deadlines for securities fraud class actions. - Hyliion projected high revenue potential, but research report...
Key Points - Kaplan Fox & Kilsheimer LLP filed a class action lawsuit against Flotek Industries,...
Key Points - Faruqi & Faruqi, LLP, Kaplan Fox & Kilsheimer LLP, Glancy Prongay Wolke &...
Most sessions tell you nothing. These 6 moved Vaxart, Inc. (VXRT) enough to be worth explaining...
Plumas Bancorp (PLBC) gives both camps something to hold. These are the 8 bullish and 0...
Andres Maldonado from H.C. Wainwright issued a price target of $18.00 for VSTM on 2026-09-14 11:35:00.The adjusted price target was set to $18.00.At the time of the announcement, VSTM was...
from Loop Capital Markets issued a price target of $25.00 for SLDB on 2026-09-14 11:34:00.The adjusted price target was set to $25.00.At the time of the announcement, SLDB was trading...
James Lex Slabbert from Jefferies issued a price target of $7.56 for LSAK on 2026-09-14 10:57:00.The adjusted price target was set to $7.56.At the time of the announcement, LSAK was...
David Williams from Williams Trading issued a price target of $9.00 for GSIT on 2026-09-14 10:37:23.The adjusted price target was set to $9.00.At the time of the announcement, GSIT was...
from Robert W. Baird issued a price target of $50.00 for RCKY on 2026-09-14 10:07:38.The adjusted price target was set to $50.00.At the time of the announcement, RCKY was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
